AbbVie Inc (ABBV)vsOscar Health Inc (OSCR)
ABBV
AbbVie Inc
$257.12
+0.83%
HEALTHCARE · Cap: $454.36B
OSCR
Oscar Health Inc
$32.77
+0.58%
HEALTHCARE · Cap: $10.19B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 320% more annual revenue ($64.39B vs $15.32B). ABBV leads profitability with a 9.8% profit margin vs 3.6%. OSCR trades at a lower P/E of 25.4x. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
OSCR
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-69.4%
Fair Value
$151.82
Current Price
$257.12
$105.30 premium
Intrinsic value data unavailable for OSCR.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 40.0%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Revenue surging 70.4% year-over-year
Earnings expanding 125.6% YoY
Conservative balance sheet, low leverage
Generating 2.0B in free cash flow
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
Moderate valuation
3.6% margin — thin
Weak financial health signals
ROE of -2.4% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.52 suggests the stock is reasonably priced for its growth.
Bull Case : OSCR
The strongest argument for OSCR centers on Revenue Growth, EPS Growth, Debt/Equity. Revenue growth of 70.4% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 72.0x leaves little room for execution misses.
Bear Case : OSCR
The primary concerns for OSCR are P/E Ratio, Profit Margin, Piotroski F-Score. Thin 3.6% margins leave little buffer for downturns.
Key Dynamics to Monitor
ABBV profiles as a value stock while OSCR is a hypergrowth play — different risk/reward profiles.
OSCR carries more volatility with a beta of 2.37 — expect wider price swings.
OSCR is growing revenue faster at 70.4% — sustainability is the question.
ABBV generates stronger free cash flow (3.2B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (73/100 vs 66/100) and 10.2% revenue growth. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Oscar Health Inc
HEALTHCARE · HEALTHCARE PLANS · USA
Oscar Health, Inc. offers health insurance products and services to individuals, families, and businesses in the United States. The company is headquartered in New York, New York.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?